Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Medtronic
Harvard Business School
Dow
Colorcon

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR ACAMPROSATE CALCIUM


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Acamprosate Calcium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00571103 ↗ Acamprosate in the Treatment of Pathological Gambling Completed Forest Laboratories Phase 4 2007-10-01 The purpose of this study is to see whether acamprosate (Campral) will curb the desire to gamble in people with pathological gambling disorder.
NCT00571103 ↗ Acamprosate in the Treatment of Pathological Gambling Completed University of Nebraska Phase 4 2007-10-01 The purpose of this study is to see whether acamprosate (Campral) will curb the desire to gamble in people with pathological gambling disorder.
NCT00571103 ↗ Acamprosate in the Treatment of Pathological Gambling Completed University of Iowa Phase 4 2007-10-01 The purpose of this study is to see whether acamprosate (Campral) will curb the desire to gamble in people with pathological gambling disorder.
NCT00591565 ↗ An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants Completed Forest Laboratories N/A 2006-06-01 This study is designed to evaluate anxious patients who are only partially responsive to typical SSRI or SNRI anti-anxiety medication therapy. Patients who are less than 50% anxiety-alleviated on their SSRI medication will be asked to join the study and be placed on Acamprosate as well. This type of add-on therapy is common in outpatient psychiatric care. This is a rater-blinded, patient open-label, non-placebo prospective study, where all subjects will receive Acamprosate for 8 weeks. This study would be the first to date in this treatment-resistant patient population, as the investigators will utilize the a comprehensive set of rating scales in order to best categorize patient responses in regards to anxiety, co-occurring depression, sleep disorders, alcohol use, and social functioning with this drug. This study may be pivotal to the initiation of future double-blind, placebo-controlled studies for this agent
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acamprosate Calcium

Condition Name

Condition Name for Acamprosate Calcium
Intervention Trials
Alcohol Dependence 2
Drug-induced Tardive Dyskinesia 1
Pathological Gambling 1
Pathological Gambling Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Acamprosate Calcium
Intervention Trials
Alcoholism 3
Tardive Dyskinesia 1
Movement Disorders 1
Dyskinesias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Acamprosate Calcium

Trials by Country

Trials by Country for Acamprosate Calcium
Location Trials
United States 5
Germany 1
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Acamprosate Calcium
Location Trials
New York 2
Illinois 1
California 1
New Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Acamprosate Calcium

Clinical Trial Phase

Clinical Trial Phase for Acamprosate Calcium
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Acamprosate Calcium
Clinical Trial Phase Trials
Completed 2
Withdrawn 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Acamprosate Calcium

Sponsor Name

Sponsor Name for Acamprosate Calcium
Sponsor Trials
Synchroneuron Inc. 2
Forest Laboratories 2
University of Nebraska 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Acamprosate Calcium
Sponsor Trials
Other 6
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Baxter
Boehringer Ingelheim
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.